Dogwood (DWTX) Therapeutics announced that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP, evaluating Halneuron to treat neuropathic pain associated with prior chemotherapy treatment is expected to occur in the first quarter of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks